Aker BioMarine AS
OSE:AKBM.OL
43.6 (NOK) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) NOK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 335.3 | 277.2 | 262.062 | 288.588 | 246.17 | 154.182 | 125.54 | 116.737 | 105.121 | 112.299 | 108.993 | 84.003 | 55.287 | 52.051 | 25.022 | 12.19 | 74.054 |
| Cost of Revenue
| 222.4 | 162.4 | 174.002 | 179.01 | 150.891 | 89.927 | 75.395 | 51.163 | 56.751 | 80.263 | 93.682 | 46.389 | 16.586 | 12.928 | 10.872 | 1.291 | 40.794 |
| Gross Profit
| 112.9 | 114.8 | 88.06 | 109.578 | 95.279 | 64.255 | 50.145 | 65.574 | 48.37 | 32.036 | 15.312 | 37.613 | 38.701 | 39.123 | 14.15 | 10.899 | 33.26 |
| Gross Profit Ratio
| 0.337 | 0.414 | 0.336 | 0.38 | 0.387 | 0.417 | 0.399 | 0.562 | 0.46 | 0.285 | 0.14 | 0.448 | 0.7 | 0.752 | 0.566 | 0.894 | 0.449 |
| Reseach & Development Expenses
| 0.4 | 4 | 2.955 | 3.905 | 5.404 | 9.07 | 0 | 3.5 | 2.1 | 8.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 21 | 14.8 | 19.182 | 17.206 | 20.099 | 15.617 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.339 |
| Selling & Marketing Expenses
| 69.1 | 67.7 | 63.568 | 65.735 | 48.309 | 20.718 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.919 |
| SG&A
| 90.1 | 82.5 | 82.75 | 82.941 | 68.408 | 36.335 | 32.932 | 30.028 | 22.649 | 25.677 | 0 | 0 | 0 | 0 | 0 | 0 | 12.258 |
| Other Expenses
| 0 | 9.1 | 16.45 | 17.938 | 19.822 | 8.591 | 0 | 0 | 0 | 0 | 0 | 40.3 | 48.083 | 46.097 | 50.389 | 37.716 | -0.368 |
| Operating Expenses
| 111.5 | 95.6 | 102.155 | 104.784 | 93.634 | 53.996 | 51.828 | 59.653 | 40.432 | 42.567 | 7.738 | 40.3 | 48.083 | 46.097 | 50.389 | 37.716 | 60.639 |
| Operating Income
| 5.3 | 22.1 | 5.845 | 18.47 | -1.666 | 10.259 | -1.338 | 16.193 | 9.81 | -11.566 | -2.964 | -6.269 | -9.382 | -13.268 | -42.623 | -26.817 | -27.38 |
| Operating Income Ratio
| 0.016 | 0.08 | 0.022 | 0.064 | -0.007 | 0.067 | -0.011 | 0.139 | 0.093 | -0.103 | -0.027 | -0.075 | -0.17 | -0.255 | -1.703 | -2.2 | -0.37 |
| Total Other Income Expenses Net
| -39.2 | -9.9 | -13.249 | -17.782 | -21.669 | -11.54 | -15.419 | -17.675 | -8.923 | -5.591 | 17.617 | -14.866 | -9.55 | -24.154 | -16.221 | -53.061 | -10.107 |
| Income Before Tax
| -33.9 | 12.2 | -7.404 | 0.688 | -23.335 | -1.281 | -16.757 | -1.482 | 0.887 | -17.157 | 14.653 | -11.463 | -18.932 | -28.747 | -52.459 | -37.716 | -37.486 |
| Income Before Tax Ratio
| -0.101 | 0.044 | -0.028 | 0.002 | -0.095 | -0.008 | -0.133 | -0.013 | 0.008 | -0.153 | 0.134 | -0.136 | -0.342 | -0.552 | -2.097 | -3.094 | -0.506 |
| Income Tax Expense
| -25 | 2.2 | 0.604 | 6.151 | 0.415 | -0.259 | 1.011 | 0.573 | 0.082 | 0.101 | 31.941 | 0.358 | 9.55 | -51.2 | 6.557 | 11.616 | -8.269 |
| Net Income
| -9 | 10 | -8.008 | -5.463 | -23.75 | -1.022 | -17.768 | -2.055 | 0.805 | -17.258 | 46.594 | -11.821 | -18.932 | 28.917 | -52.459 | -61.808 | -29.217 |
| Net Income Ratio
| -0.027 | 0.036 | -0.031 | -0.019 | -0.096 | -0.007 | -0.142 | -0.018 | 0.008 | -0.154 | 0.427 | -0.141 | -0.342 | 0.556 | -2.097 | -5.071 | -0.395 |
| EPS
| -0.1 | 0.11 | -0.091 | -0.07 | -0.34 | -0.015 | 0 | -0.03 | 0.01 | -0.25 | 0 | -0.011 | -0.02 | 0.054 | -0.58 | -0.69 | -0.38 |
| EPS Diluted
| -0.1 | 0.11 | -0.091 | -0.07 | -0.34 | -0.015 | 0 | -0.03 | 0.012 | -0.25 | 0 | -0.011 | -0.02 | 0.054 | -0.58 | -0.69 | -0.38 |
| EBITDA
| 45.8 | 75.6 | 56.927 | 66.717 | 35.281 | 35.315 | 15.059 | 32.59 | 25.337 | 6.452 | 11.854 | 23.105 | 0.503 | 6.634 | -14.15 | 23.232 | -6.983 |
| EBITDA Ratio
| 0.137 | 0.273 | 0.217 | 0.231 | 0.143 | 0.229 | 0.12 | 0.279 | 0.241 | 0.057 | 0.109 | 0.275 | 0.009 | 0.127 | -0.566 | 1.906 | -0.094 |